North Carolina women’s basketball player, Jessica Breland, has won the Honda Inspiration Award. This milestone comes as a result of her admirable comeback to the NCAAW ranks after getting treatment for a particular case of Hodgkin’s lymphoma.
Breland, a beloved figure in her community and amongst her team members, was initially diagnosed with the disease in May of 2009. Upon receiving the news from her doctors, she opted to sit out for a year while receiving chemotherapy.
She then proceeded to return the following year and average nearly 20 points per game and 6.8 rebounds en route to becoming one of the top-tier players on her team. On top of being a model for perseverance and a testament to the power of hard work, Breland was also an excellent student as she maintained at least a 3.0 GPA in her last four semesters to earn a spot on the ACC honor roll.
Selected by the New York Liberty in the second round of the WNBA draft last month, Breland hopes to take her undeniably unique skill set and work ethic to the next level in the professional ranks.
Breland will be presented with the award in a special ceremony on June 27 in New York.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...